Published in Arch Neurol on February 01, 2007
MRI in multiple sclerosis: current status and future prospects. Lancet Neurol (2008) 2.08
Cerebral atrophy as outcome measure in short-term phase 2 clinical trials in multiple sclerosis. Neuroradiology (2010) 0.97
Establishing pathological cut-offs of brain atrophy rates in multiple sclerosis. J Neurol Neurosurg Psychiatry (2015) 0.90
Characteristics of multiple sclerosis at onset and delay of diagnosis and treatment in Spain (the Novo Study). J Neurol (2010) 0.79
Clinical and conventional MRI predictors of disability and brain atrophy accumulation in RRMS. A large scale, short-term follow-up study. J Neurol (2008) 0.78
What causes multiple sclerosis to worsen? Arch Neurol (2007) 0.75
Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med (2010) 13.82
Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med (2006) 7.18
Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. Lancet Neurol (2013) 6.18
Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med (2006) 5.20
Further Implications of Off-Label Use of Acetazolamide in the Management of Moyamoya Disease in Japan: Response. Radiology (2017) 4.99
T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nat Med (2010) 4.78
Altered resting state networks in mild cognitive impairment and mild Alzheimer's disease: an fMRI study. Hum Brain Mapp (2005) 4.11
PML in a patient treated with dimethyl fumarate from a compounding pharmacy. N Engl J Med (2013) 4.02
Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Hum Mol Genet (2008) 3.93
Pathway and network-based analysis of genome-wide association studies in multiple sclerosis. Hum Mol Genet (2009) 3.92
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet (2011) 3.76
Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study. Lancet (2008) 3.68
Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci. Ann Neurol (2011) 3.52
MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study. Lancet Neurol (2007) 3.47
Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol (2009) 3.42
Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Lancet Neurol (2011) 3.16
Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol (2009) 2.82
Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol (2011) 2.75
Chronic cerebrospinal venous insufficiency and multiple sclerosis. Ann Neurol (2010) 2.63
Small vessel disease and general cognitive function in nondisabled elderly: the LADIS study. Stroke (2005) 2.59
Progression of white matter hyperintensities and incidence of new lacunes over a 3-year period: the Leukoaraiosis and Disability study. Stroke (2008) 2.57
Intracortical lesions in multiple sclerosis: improved detection with 3D double inversion-recovery MR imaging. Radiology (2005) 2.47
Bright light treatment in elderly patients with nonseasonal major depressive disorder: a randomized placebo-controlled trial. Arch Gen Psychiatry (2011) 2.45
Heterogeneity of small vessel disease: a systematic review of MRI and histopathology correlations. J Neurol Neurosurg Psychiatry (2010) 2.44
MRI and the diagnosis of multiple sclerosis: expanding the concept of "no better explanation". Lancet Neurol (2006) 2.44
Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. Brain (2002) 2.30
Magnetic resonance imaging pattern recognition in hypomyelinating disorders. Brain (2010) 2.19
Loss of 'small-world' networks in Alzheimer's disease: graph analysis of FMRI resting-state functional connectivity. PLoS One (2010) 2.12
Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol (2005) 2.10
MRI in multiple sclerosis: current status and future prospects. Lancet Neurol (2008) 2.08
Cortical lesions in multiple sclerosis: combined postmortem MR imaging and histopathology. AJNR Am J Neuroradiol (2005) 2.07
Grey matter volume in a large cohort of MS patients: relation to MRI parameters and disability. Mult Scler (2011) 2.07
Lack of association between antimyelin antibodies and progression to multiple sclerosis. N Engl J Med (2007) 2.06
Safety, anxiety and natalizumab continuation in JC virus-seropositive MS patients. Mult Scler (2013) 2.04
Grey matter pathology in multiple sclerosis. Lancet Neurol (2008) 1.97
Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet (2004) 1.93
Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo. Nat Biotechnol (2009) 1.90
Impact of white matter hyperintensities scoring method on correlations with clinical data: the LADIS study. Stroke (2006) 1.88
Health-related quality of life in multiple sclerosis: effects of natalizumab. Ann Neurol (2007) 1.88
Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. Lancet Neurol (2013) 1.84
Precuneus atrophy in early-onset Alzheimer's disease: a morphometric structural MRI study. Neuroradiology (2007) 1.80
Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. Lancet Neurol (2011) 1.79
Imaging markers for Alzheimer disease: which vs how. Neurology (2013) 1.76
Unusual variants of Alexander's disease. Ann Neurol (2005) 1.76
On the etiology of incident brain lacunes: longitudinal observations from the LADIS study. Stroke (2008) 1.75
Clinico-pathological evidence that axonal loss underlies disability in progressive multiple sclerosis. Mult Scler (2010) 1.72
Association between pathological and MRI findings in multiple sclerosis. Lancet Neurol (2012) 1.70
Improved detection of active multiple sclerosis lesions: 3D subtraction imaging. Radiology (2010) 1.68
Assessment of JC virus DNA in blood and urine from natalizumab-treated patients. Ann Neurol (2010) 1.68
No association of abnormal cranial venous drainage with multiple sclerosis: a magnetic resonance venography and flow-quantification study. J Neurol Neurosurg Psychiatry (2010) 1.68
Accelerated aging, decreased white matter integrity, and associated neuropsychological dysfunction 25 years after pediatric lymphoid malignancies. J Clin Oncol (2013) 1.67
Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: a longitudinal study. Neurobiol Aging (2008) 1.67
Structural magnetic resonance imaging in the practical assessment of dementia: beyond exclusion. Lancet Neurol (2002) 1.64
Microbleeds do not affect rate of cognitive decline in Alzheimer disease. Neurology (2012) 1.62
Overdiagnosis of multiple sclerosis and magnetic resonance imaging criteria. Ann Neurol (2005) 1.61
Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease. Alzheimers Dement (2011) 1.59
Model-free group analysis shows altered BOLD FMRI networks in dementia. Hum Brain Mapp (2009) 1.59
Patients with Alzheimer disease with multiple microbleeds: relation with cerebrospinal fluid biomarkers and cognition. Stroke (2009) 1.57
Location of brain lesions predicts conversion of clinically isolated syndromes to multiple sclerosis. Neurology (2012) 1.57
Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in Alzheimer's disease. J Alzheimers Dis (2012) 1.57
A new leukoencephalopathy with brainstem and spinal cord involvement and high lactate. Ann Neurol (2003) 1.57
White matter tract integrity in aging and Alzheimer's disease. Hum Brain Mapp (2009) 1.57
Whole-brain atrophy rate and cognitive decline: longitudinal MR study of memory clinic patients. Radiology (2008) 1.56
Remyelinated lesions in multiple sclerosis: magnetic resonance image appearance. Arch Neurol (2003) 1.55
Resting-state fMRI changes in Alzheimer's disease and mild cognitive impairment. Neurobiol Aging (2011) 1.54
Diffusion changes predict cognitive and functional outcome: the LADIS study. Ann Neurol (2013) 1.54
Differential item functioning of the Functional Independence Measure in higher performing neurological patients. J Rehabil Med (2005) 1.54
Histopathologic correlates of radial stripes on MR images in lysosomal storage disorders. AJNR Am J Neuroradiol (2005) 1.53
Frontal-striatal dysfunction during planning in obsessive-compulsive disorder. Arch Gen Psychiatry (2005) 1.53
Risk of rapid global functional decline in elderly patients with severe cerebral age-related white matter changes: the LADIS study. Arch Intern Med (2007) 1.52
Diagnostic accuracy of consensus diagnostic criteria for frontotemporal dementia in a memory clinic population. Dement Geriatr Cogn Disord (2008) 1.51
Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease. Neurology (2013) 1.51
Clinical effect of neutralizing antibodies to interferon beta that persist long after cessation of therapy for multiple sclerosis. Arch Neurol (2010) 1.50
Disability outcome measures in multiple sclerosis clinical trials: current status and future prospects. Lancet Neurol (2012) 1.50
The clinical profile of right temporal lobe atrophy. Brain (2009) 1.46
The efficacy of natalizumab in patients with relapsing multiple sclerosis: subgroup analyses of AFFIRM and SENTINEL. J Neurol (2009) 1.46
Noradrenaline mediates amygdala activation in men and women during encoding of emotional material. Neuroimage (2005) 1.45
Spatiotemporal distribution of white matter lesions in relapsing-remitting and secondary progressive multiple sclerosis. Mult Scler (2012) 1.45
Pharmacogenomics of interferon-beta therapy in multiple sclerosis: baseline IFN signature determines pharmacological differences between patients. PLoS One (2008) 1.43
Improved in vivo detection of cortical lesions in multiple sclerosis using double inversion recovery MR imaging at 3 Tesla. Eur Radiol (2010) 1.41